Treatment patterns and costs in patients with generalised anxiety disorder: One-year retrospective analysis of data from national registers in Sweden

European Psychiatry

Volumn 28, Issue 2, 2013, Pages 125-133

  Sandelin, R ^a   Kowalski, J ^b   Ahnemark, E ^a   Allgulander, C ^b  

^a PFIZER INC   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Comorbidity; Cost; Generalised anxiety disorder; Medical record linkage; Pharmacoepidemiology

Indexed keywords

ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; HYPNOTIC AGENT; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ANXIETY DISORDER; ARTHROPATHY; ARTICLE; CHRONIC LUNG DISEASE; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE DURATION; DRUG USE; FEMALE; GENERALIZED ANXIETY DISORDER; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; HYPERTENSION; ICD-10; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OUTPATIENT CARE; PERSONALITY DISORDER; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOSIS; REGISTER; RETROSPECTIVE STUDY; SWEDEN; THYROID DISEASE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; REGISTRIES; RETROSPECTIVE STUDIES; SWEDEN; TREATMENT OUTCOME;

EID: 84873525961     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2012.02.003     Document Type: Article

References (48)

1. Allgulander C. Novel approaches to treatment of generalized anxiety disorder. Curr Opin Psychiatry 2010, 23:37-42.
2. Allgulander C., Nilsson B. A nationwide study in primary health care: one out of four patients suffers from anxiety and depression. Lakartidningen 2003, 100:832-838.
3. Allgulander C., Nutt D. Benzodiazepines. Encyclopedia of psychopharmacology 2010, 218-223. Springer-Verlag, Heidelberg. 1st ed. I. Stolerman, M. Lader (Eds.).
4. Ansseau M., Fischler B., Dierick M., Mignon A., Leyman S. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study. Eur Psychiatry 2005, 20:229-235.
5. Baldwin D.S., Waldman S., Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 2011, 14(5):697-710.
6. Bandelow B., Zohar J., Hollander E., Kasper S., Moller H.J., Allgulander C., et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008, 9:248-312.
7. Beekman A.T., de Beurs E., van Balkom A.J., Deeg D.J., van Dyck R., van Tilburg W. Anxiety and depression in later life: co-occurrence and communality of risk factors. Am J Psychiatry 2000, 157:89-95.
8. Belanger L., Ladouceur R., Morin C.M. Generalized anxiety disorder and health care use. Can Fam Physician 2005, 51:1362-1363.
9. Bereza B.G., Machado M., Einarson T.R. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. Clin Ther 2009, 31:1279-1308.
10. Carter C.S., Maddock R.J. Chest pain in generalized anxiety disorder. Int J Psychiatry Med 1992, 22:291-298.
11. Carter R.M., Wittchen H.U., Pfister H., Kessler R.C. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety 2001, 13:78-88.
12. Chang C.M., Wu E.C., Chang I.S., Lin K.M. Benzodiazepine and risk of hip fractures in older people: a nested case-control study in Taiwan. Am J Geriatr Psychiatry 2008, 16:686-692.
13. Chou K.L. Age at onset of generalized anxiety disorder in older adults. Am J Geriatr Psychiatry 2009, 17:455-464.
14. Culpepper L. Generalized anxiety disorder and medical illness. J Clin Psychiatry 2009, 70(Suppl. 2):20-24.
15. Davidson J.R., Bose A., Korotzer A., Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004, 19:234-240.
16. Davidson J.R., Zhang W., Connor K.M., Ji J., Jobson K., Lecrubier Y., et al. A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD). J Psychopharmacol 2010, 24:3-26.
17. Gelenberg A.J., Lydiard R.B., Rudolph R.L., Aguiar L., Haskins J.T., Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 2000, 283:3082-3088.
18. Goodwin R.D., Stein M.B. Generalized anxiety disorder and peptic ulcer disease among adults in the United States. Psychosom Med 2002, 64:862-866.
19. Hoffman D.L., Dukes E.M., Wittchen H.U. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008, 25:72-90.
20. Katzman M.A. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 2009, 23:103-120.
21. Kennedy B.L., Schwab J.J. Utilization of medical specialists by anxiety disorder patients. Psychosomatics 1997, 38:109-112.
22. Kessler R.C., Andrade L.H., Bijl R.V., Offord D.R., Demler O.V., Stein D.J. The effects of co-morbidity on the onset and persistence of generalized anxiety disorder in the ICPE surveys. International Consortium in Psychiatric Epidemiology. Psychol Med 2002, 32:1213-1225.
23. Kessler R.C., DuPont R.L., Berglund P., Wittchen H.U. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12months in two national surveys. Am J Psychiatry 1999, 156:1915-1923.
24. Kessler R.C., Wang P.S. The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu Rev Public Health 2008, 29:115-129.
25. Lieb R., Becker E., Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005, 15:445-452.
26. Liu X., Ye W., Watson P., Tepper P. Use of benzodiazepines, hypnotics, and anxiolytics in major depressive disorder: association with chronic pain diseases. J Nerv Ment Dis 2010, 198(8):544-550.
27. Mets M.A., Volkerts E.R., Olivier B., Verster J.C. Effect of hypnotic drugs on body balance and standing steadiness. Sleep Med Rev 2010, 14:259-267.
28. Mojtabai R., Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 2010, 67:26-36.
29. Munk-Jorgensen P., Allgulander C., Dahl A.A., Foldager L., Holm M., Rasmussen I., et al. Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden. Psychiatr Serv 2006, 57:1738-1744.
30. National Institute for Health and Clinical Excellence (NICE). Clinical guideline 22. Anxiety (amended); 2007. http://www.nice.org.uk/nicemedia/pdf/CG022NICEguidelineamended.pdf.
31. Nutt D., Argyropoulos S., Hood S., Potokar J. Generalized anxiety disorder: a comorbid disease. Eur Neuropsychopharmacol 2006, 16(Suppl. 2):S109-S118.
32. Pollack M.H. Refractory generalized anxiety disorder. J Clin Psychiatry 2009, 70(Suppl. 2):32-38.
33. Porensky E.K., Dew M.A., Karp J.F., Skidmore E., Rollman B.L., Shear M.K., et al. The burden of late-life generalized anxiety disorder: effects on disability, health-related quality of life, and healthcare utilization. Am J Geriatr Psychiatry 2009, 17:473-482.
34. Revicki D.A., Brandenburg N., Matza L., Hornbrook M.C., Feeny D. Health-related quality of life and utilities in primary-care patients with generalized anxiety disorder. Qual Life Res 2008, 17:1285-1294.
35. Rickels K., Zaninelli R., McCafferty J., Bellew K., Iyengar M., Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003, 160:749-756.
36. Roy-Byrne P.P., Wagner A. Primary care perspectives on generalized anxiety disorder. J Clin Psychiatry 2004, 65(Suppl. 13):20-26.
37. Ruscio A., Chiu W., Byrne-Roy P., Stang P., Stein D., Wittchen H.U., et al. Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication. J Anxiety Disord 2007, 21:662-676.
38. Science Daily Science Reference Library. Rockville, MD, United States; 2011. http://www.sciencedaily.com/articles/p/psychoactive_drug.htm.
39. Södra Regionvårdsnämnden Regionala priser och ersättningar för Södra sjukvårdsregionen 2008; 2007. Available from: http://www.skane.se/upload/Webbplatser/Sodra%20regionvardsnamnden/prislista/2008/helaprislistan2008.pdf.
40. Souetre E., Lozet H., Cimarosti I., Martin P., Chignon J.M., Ades J., et al. Cost of anxiety disorders: impact of comorbidity. J Psychosom Res 1994, 38(Suppl. 1):151-160.
41. Sveriges Kommuner och Landsting. Förteckning E för perioden 2007-01-01 - 2009-12-31 till riksavtalet för utomlänsvård, dnr 2006/0804; 2006. Available from: http://websesam.jll.se/diariet/files/42a4eb49-1b43-43f3-97aa-4c0ed952c681.pdf.
42. Swedish Council on Health Technology Assessment. Treatment of anxiety disorders: a systematic review. Report No. 171/1+2. 2005.
43. Swedish Council on Health Technology Assessment. Treatment of insomnia in adults [in Swedish]. Report No. 199. 2010.
44. The Swedish Board of Health and Welfare. The Prescribed Drug Register, 2005-2011.
45. The Swedish Board of Health and Welfare. Socialstyrelsen.se/statistik/statistikdatabas Diagnoser i slutenvård (Diagnosis of inpatient visits). 2011.
46. Wittchen H.U. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002, 16:162-171.
47. Wittchen H.U., Zhao S., Kessler R.C., Eaton W.W. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:355-364.
48. Wittchen H.U., Carter R.M., Pfister H., Montgomery S.A., Kessler R.C. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 2000, 15:319-328.